Literature DB >> 6603979

Steady state disposition of chloroquine in patients with rheumatoid disease.

M Frisk-Holmberg, Y Bergqvist, B Domeij-Nyberg.   

Abstract

The steady state disposition of chloroquine and its major metabolites, monodesethyl and bidesethyl chloroquine, were determined in 6 patients on long-term treatment for rheumatic disease with 99-155 mg base/day. The total body clearance of chloroquine was 0.35 l/kg/h and that of its metabolites was much higher. The renal clearance was the same for all compounds measured, approximately equal to 0.1 l/kg/h. Currently recommended dosage schedules appear to be too high in certain cases.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6603979     DOI: 10.1007/bf00607097

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  4 in total

1.  Pharmacokinetics of antimalarials and proposals for dosage regimens.

Authors:  W A Ritschel; G V Hammer; G A Thompson
Journal:  Int J Clin Pharmacol Biopharm       Date:  1978-09

2.  Sensitive high-performance liquid chromatographic analysis for chloroquine in body fluids. Application to studies of drug resistance in Plasmodium falciparum.

Authors:  M A Staiger; P Nguyen-Dinh; F C Churchill
Journal:  J Chromatogr       Date:  1981-09-11

3.  Chloroquine serum concentration and side effects: evidence for dose-dependent kinetics.

Authors:  M Frisk-Holmberg; Y Bergkvist; B Domeij-Nyberg; L Hellström; F Jansson
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

4.  Sensitive method for the determination of chloroquine and its metabolite desethyl-chloroquine in human plasma and urine by high-performance liquid chromatography.

Authors:  Y Bergqvist; M Frisk-Holmberg
Journal:  J Chromatogr       Date:  1980-11-14
  4 in total
  8 in total

Review 1.  Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements.

Authors:  J Ducharme; R Farinotti
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

2.  Further support for changes in chloroquine disposition and metabolism between a low and a high dose.

Authors:  M Frisk-Holmberg; Y Bergqvist; E Termond
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

3.  The single dose kinetics of chloroquine and its major metabolite desethylchloroquine in healthy subjects.

Authors:  M Frisk-Holmberg; Y Bergqvist; E Termond; B Domeij-Nyberg
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  Chloroquine levels in blood during chronic treatment of patients with rheumatoid arthritis.

Authors:  P Augustijns; P Geusens; N Verbeke
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 5.  Clinical pharmacokinetics of slow-acting antirheumatic drugs.

Authors:  S E Tett
Journal:  Clin Pharmacokinet       Date:  1993-11       Impact factor: 6.447

6.  Influence of CYP2C8, CYP3A4, and CYP3A5 Host Genotypes on Early Recurrence of Plasmodium vivax.

Authors:  Anne C G Almeida; Maria C B Puça; Erick F G Figueiredo; Laila R Barbosa; Yanka E A R Salazar; Emanuelle L Silva; Marcelo A M Brito; André M Siqueira; José L F Vieira; Marcus V G Lacerda; Wuelton M Monteiro; Gisely C Melo
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

Review 7.  Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties.

Authors:  Cornelis Smit; Mariska Y M Peeters; John N van den Anker; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2020-06       Impact factor: 6.447

Review 8.  Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection.

Authors:  Melanie R Nicol; Abhay Joshi; Matthew L Rizk; Philip E Sabato; Radojka M Savic; David Wesche; Jenny H Zheng; Jack Cook
Journal:  Clin Pharmacol Ther       Date:  2020-09-01       Impact factor: 6.903

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.